RIETE Score (VTE Recurrence) Calculator

Clinical calculation support · Verify results before clinical use

Risk assessment inputs

Enter the patient's clinical findings. This implementation reflects the RIETE 3-month major-bleeding score, not VTE recurrence risk.

— Score
Score criterion: age >75 years (+1 point).
Anemia threshold: hemoglobin <13 g/dL in men or <12 g/dL in women.
Creatinine >1.2 mg/dL contributes 1.5 points.
Enter the measured hemoglobin value.
Recent major bleeding
Cancer
Clinically overt pulmonary embolism at presentation

About the RIETE bleeding score

The RIETE score was developed to stratify the risk of major bleeding during the first three months of anticoagulant treatment in patients presenting with acute venous thromboembolism. The referenced 2008 publication is a bleeding-risk model, not a recurrence score.

Score variables

VariableCriterionPoints
Recent major bleedingWithin 15 days before VTE2
Serum creatinine>1.2 mg/dL1.5
AnemiaHemoglobin <13 g/dL (men) or <12 g/dL (women)1.5
CancerPresent1
Clinically overt PEPresent at baseline1
Age>75 years1

Risk categories in the derivation cohort

ScoreCategory3-month major bleeding incidence
0Low0.3%
1–4Intermediate2.6%
>4High7.3%

References

Ruiz-Giménez N, et al.Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26–31. PMID: 18612534.View PubMed record · DOI: 10.1160/TH08-03-0193
de Winter MA, et al.Prediction models for recurrence and bleeding in patients with venous thromboembolism: a systematic review and critical appraisal. Thrombosis Research. 2021;199:85–96. This review lists the RIETE model as a 3-month bleeding prediction model.View article page